After conducting quality appraisal on the remaining CPGs, and checking for quality, publication time and comprehensiveness, we finally included the following guidelines: “Intravitreal injection of anti-vascular endothelial growth factor agents for ocular vascular diseases; Clinical practice guideline”(2018) [63] developed by Homayoun Nikkhah et al., and “Ranibizumab for treating choroidal neovascularisation associated with pathological myopia”(2013) [64] developed by National Institute for Health and Care Excellence (NICE). This evidence concerns the gene VEGFA and myopia.